Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for Ligand Pharmaceuticals (LGND) over the last 7 years, with Q3 2025 value amounting to $172000.0.

  • Ligand Pharmaceuticals' Depreciation and Depletion fell 7663.04% to $172000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 3346.59%. This contributed to the annual value of $2.3 million for FY2024, which is 2068.97% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Depreciation and Depletion stood at $172000.0, which was down 7663.04% from $264000.0 recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Depreciation and Depletion ranged from a high of $736000.0 in Q3 2024 and a low of $172000.0 during Q3 2025